Abstract: Objective To remind clinicians to pay close attention to medication safety when doxorubicin liposomes and paclitaxel (albumin-bound type) are used in combination. Methods One case of a 43-year-old female patient with grade 3 hand-foot syndrome and grade 2 intertrigo-like eruption after combined use of doxorubicin liposome and paclitaxel (albumin-bound type) was analyzed. Literature about the clinical manifestations, pathogenesis and prevention of skin toxicity caused by the above two drugs was reviewed. Results The patient's hand-foot syndrome was probably caused by doxorubicin liposomes, and the intertrigo-like eruption by the combined use of doxorubicin liposomes and paclitaxel (albumin-bound). After such symptomatic interventions as dose reduction, delayed chemotherapy and traditional Chinese medicine, the patient' s skin symptoms were gradually relieved. Conclusion The combined use of doxorubicin liposomes and paclitaxel (albumin-bound type) may cause serious skin toxicity and impact the quality of life of patients, which deserves the attention of clinicians. Patients should be better informed of the related risk and take precautions.

Key words: doxorubicin liposome injection, paclitaxel (albumin-binding), hand-foot syndrome, intertrigo-like eruption, adverse drug reaction